comparemela.com

Latest Breaking News On - Orphan drug exclusivity - Page 11 : comparemela.com

Fennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

~ Strong PEDMARK® Commercial Momentum Building in 2023 with Broad Payor and Medicaid Coverage ~ ~ PEDMARK® Permanent J-Code Effective April 1, 2023 ~ ~ Recent Positive CHMP Opinion in EU. | May 11, 2023

New yorkUnited statesRosty raykovRobert andradeLindsay roccoLandierw ototoxicityClinical oncology groupUs centers for medicare medicaid servicesEuropean medicines agencyFennec pharmaceuticalsNational comprehensive cancer networkExchange commissionDevelopment rd expensesOregon healthDrug administrationElixir health public relations

Jazz Pharmaceuticals Announces First Quarter 2023 Financial Results and Affirms 2023 Financial Guidance

/PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2023, affirmed 2023 financial guidance and.

United kingdomUnited statesOxybate xywavKristin bhavnaniRob iannoneEpidiolex epidyolexBruce cozaddAndrean flynnUniversity of texas md anderson cancer centerRoche ltdHead of global corporate communicationsHikma pharmaceuticalsDepartment of gastrointestinal medical oncologyCompany annual report on formGw pharmaceuticalsExchange commission

FDA Grants Final Approval for Treatment of Cataplexy in Adults With Narcolepsy

Treatment is now the first and only once-at-bedtime oxybate to be approved by the FDA for individuals with narcolepsy.

Greg divisAvadel pharmaceuticalsDrug administrationOrphan drug exclusivity

Avadel Pharma Gains 8% As FDA Clears Lumryz To Treat EDS

Shares of Avadel Pharmaceuticals plc (AVDL) are gaining over 8% on Tuesday morning after the company received FDA's clearance for Lumryz to treat excessive daytime sleepiness.

Greg divisUs food drug administrationAvadel pharmaceuticalsDrug administrationOrphan drug exclusivityChief executive officerAvadel pharma

Avadel Pharmaceuticals : Regulation FD Presentation - Form 8-K

Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime. | May 1, 2023

United statesCourtney turianoMichaelj thorpyGabriella greigGreg divisAvadel pharmaceuticals announces finalAvadel pharmaceuticalsAlbert einstein college of medicineUs food drug administrationSecurities exchangeCompany annual report on formWake disorders center at montefiore medicalExchange commissionStern investor relations incExtended release oral suspensionOnly once at bedtime oxybate

vimarsana © 2020. All Rights Reserved.